Release 5 Preview #2

This page is part of the FHIR Specification (v4.4.0: R5 Preview #2). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.4.2.16621 HL7 v3 Value Set ActSubstanceAdminSubstitutionCode

Vocabulary

Work Group

Maturity Level: 1

Draft

Use Context: Any

This value set (http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode) is defined as part of HL7 v3.

Summary

Defining URL:

http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode

Version:

2014-03-26

Name:

v3.ActSubstanceAdminSubstitutionCode

Title:

V3 Value SetActSubstanceAdminSubstitutionCode

Definition:

No Description Provided

OID:

2.16.840.1.113883.1.11.16621 (for OID based terminology systems)

Source Resource

XML / JSON

This value set is used in the following places:

Resource: MedicationRequest.substitution.allowed[x] (boolean|CodeableConcept / Example)
Resource: MedicationDispense.substitution.type (CodeableConcept / Example)

4.4.2.16621.1 Content Logical Definition

Include codes from http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution where concept is-a _ActSubstanceAdminSubstitutionCode

Exclude these codes as defined in http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

Code	Display
_ActSubstanceAdminSubstitutionCode	ActSubstanceAdminSubstitutionCode	Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.

This value set includes codes based on the following rules:

4.4.2.16621.2 Expansion

This expansion generated 03 May 2020

This value set contains 9 concepts

Expansion based on v3 Code System substanceAdminSubstitution v2019-07-31 (CodeSystem)

All codes from system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

Code	Display	Logical Definition (CLD)
E	equivalent	Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
EC	equivalent composition	Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
BC	brand composition	Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
G	generic composition	Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
TE	therapeutic alternative	Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
TB	therapeutic brand	Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
TG	therapeutic generic	Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
F	formulary	Description: This substitution was performed or is permitted based on formulary guidelines.
N	none	No substitution occurred or is permitted.